• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Children benefit from nearly 300 meds in development

Children benefit from nearly 300 meds in development

January 13, 2012
CenterWatch Staff

Today, a whopping 282 medicines to treat children and adolescents are in clinical trials or under review by the FDA, according to a report by Pharmaceutical Research and Manufacturers of America (PhRMA).

Medicine has been key in recent decades in fighting diseases that impact children. New vaccines, antibiotics, and major treatments protect children against many childhood and infections diseases, as well as cancer. With 30 years of advancement, the percentage of children with cancer surviving for five years of longer has increased by 24 percentage points.

Of the nearly 300 medicines in the report, 54 are for cancer, 49 for infectious diseases, 48 for genetic disorders and 25 for neurologic disorders. In addition to developing new medicines, researches are testing existing medicines to determine safe and effective dosage levels for children.

Biopharmaceutical research companies are working to continue this progress, which has plunged infant mortality to record lows, but the termination of the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) in October 2012, unless reauthorized or made permanent by Congress, will cease many research possibilities.

“Reauthorization of these pivotal programs is essential to continued progress in children’s health,” said John J. Castellani, president and CEO of PhRMA. “Permanent reauthorization would provide much-needed predictability and certainty, to the benefit of regulators, innovative companies and, ultimately, children.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing